Browsing by Author "Dhawan, Gagan"
Now showing items 1-4 of 4
-
Development of Dimethylisoxazole-Attached Imidazo[1,2‑a]pyridines as Potent and Selective CBP/P300 Inhibitors
Muthengi, Alex; Wimalasena, Virangika K.; Yosief, Hailemichael O.; Bikowitz, Melissa J.; Sigua, Logan H.; Wang, Tingjian; Li, Deyao; Zhang, Wei; Qi, Jun; Schönbrunn, Ernst; Amaro, Rommie E.; Erickson, Jon; Liu, Shuai; Dhawan, Gagan; Gaieb, Zied (2021)The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodo main extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET ... -
One-pot and catalyst-free synthesis of pyrroloquinolinediones and quinolinedicarboxylates†
Zhang, Xiaofenga; Dhawan, Gagan; Muthengi, Alex; Liu, Shuai; Wang, Wei; Legrisa, Marc; Zhang, Wei (2017)A method for the catalyst-free synthesis of pyrroloquinolinediones and quinolinedicarboxylates is develo ped through a one-pot synthesis involving denitrogenation of azide, benzisoxazole formation, aza-Diels– Alder ... -
Sequential (3 + 2) cycloaddition and (5 + n) annulation for modular synthesis of dihydrobenzoxazines, tetrahydrobenzoxazepines and tetrahydrobenzoxazocines†
Muthengi, Alex; Zhang, Xiaofeng; Dhawan, Gagan; Zhang, Wensheng; Corsinia, Francesca; Zhang, Wei (2018-06)A two-step method for the (3 + 2) cycloaddition of azomethine ylides followed by a double SN2 substi tution-based (5 + n) annulation is introduced for the modular synthesis of dihydrobenzoxazine, tetra hydrobenzoxazepine ... -
Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
Liu, Shuai; Yosief, Hailemichael O.†; Dai, Lingling; Huang, He; Dhawan, Gagan; Zhang, Xiaofeng; Muthengi, Alex; Roberts, Justin; Buckley, Dennis L.; Perry, Jennifer A.; Wu, Lei; Bradner, James E.; Qi, Jun; Zhang, Wei (2018)The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are ...